Provided herein, in some embodiments, are artificial secretion peptides capable of directing secretion from Lactobacillus for use, for example, in producing heterologous proteins, including therapeutic proteins.

This disclosure pertains to pharmaceutical compositions of aerosolized compositions containing mitochondria, methods of preparing and using the compositions, and devices for administering the compositions.

This disclosure pertains to pharmaceutical compositions of aerosolized compositions containing mitochondria, methods of preparing and using the compositions, and devices for administering the compositions.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

Disclosed herein is a composition including Lactobacillus plantarum TWK10 deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession number CGMCC 13008 for use in treating sarcopenia and for use in maintaining and/or increasing muscle mass and/or strength in an elderly subject.

A method for separating cells in a biofluid includes pretreating the biofluid by introducing a predetermined amount of a cocktail of antibodies, flowing the pretreated biofluid through a microfluidic separation channel, and applying acoustic energy to the pretreated biofluid within the microfluidic separation channel. A system for microfluidic cell separation, capable of separating target cells from non-target cells in a biofluid includes at least one microfluidic separation channel, a source of biofluid, a source of an additive including the cocktail of antibodies, and at least one acoustic transducer coupled to the microfluidic separation channel. A kit for microfluidic cell separation is also disclosed. A method of facilitating separation of cells is also disclosed.

A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (iCAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the iCAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.

Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions including apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do not reduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm including administration of a composition including apoptotic cells or an apoptotic cell supernatant.

The infusion pump for stem cells includes a liquor storage device and an infusion pipe. The inner wall of the liquor storage sac of the liquor storage device and inner walls of the infusion pipe are provided with an anionic protective film to prevent stem cells from adhering to the infusion pump by mutual repulsion between anions. The infusion method includes checking an infusion pump for integrity, losing a liquor stop clamp, injecting a mixed liquor of stem cells and medicine, covering a protective cap, opening the liquor stop clamp, closing the liquor stop clamp for use, connecting an external cone joint with a venous cannula, and then opening the liquor stop clamp. The method also includes steadily placing the liquor storage sac on a horizontal plane using an auxiliary placing device, and after infusion ends, closing the liquor stop clamp, and disconnecting the external cone joint.

The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.